| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | -0.078 | 0.03 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.12 | 0.03 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.03 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | -0.074 | 0.03 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.085 | 0.03 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.079 | 0.03 |
| mRNA | NVP-ADW742 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.03 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.066 | 0.03 |
| mRNA | RAF265 | FIMM | pan-cancer | AAC | -0.41 | 0.03 |
| mRNA | AT7867 | CTRPv2 | pan-cancer | AAC | -0.078 | 0.03 |